

# Women's Cancer Research Centre

## Research publications 2019

1. Barker HE, Scott CL. Preclinical rare cancer research to inform clinical trial design. *Nat Rev Cancer*. 2019;19(9):481-2.
2. Blagden SP, Hamilton AL, Mileskin L, Wong S, Michael A, Hall M, et al. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2019;25(5):1472-8.
3. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nature communications*. 2019;10(1):3935.
4. Hickey M, Richards AM. Vaginal laser treatment-first, do no harm. *Menopause*. 2019;26(8):814-5.
5. How JA, Marino JL, Grover SR, Heloury Y, Sullivan M, Mellor A, et al. Surgically Managed Ovarian Masses at the Royal Children's Hospital, Melbourne -19 Year Experience. *J Pediatr Surg*. 2019;54(9):1913-20.
6. Knox B, Dobrotwir A, Ades A. Isolated uterine metastasis from a lung adenocarcinoma. *BMJ Case Rep*. 2019;12(12).
7. Kondrashova O, Scott CL. Clarifying the role of EMSY in DNA repair in ovarian cancer. *Cancer*. 2019;125(16):2720-4.
8. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, et al. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. *Cancer Discov*. 2019;9(2):210-9.
9. Rajasooriyar C, Lin MY, Kalra R, Lim A, Narayan K. The role of positron emission tomography in the selection of patients for salvage hysterectomy following chemoradiotherapy for locally advanced cervical cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2019.
10. Sykes P, Eva L, van der Griend R, McNally O, Blomfield P, Brand A, et al. Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. *Gynecologic oncology*. 2019;153(2):292-6.
11. Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, et al. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. *Gynecologic oncology*. 2019;154(3):531-8.



12. Wakefield MJ, Nestic K, Kondrashova O, Scott CL. Diverse mechanisms of PARP inhibitor resistance in ovarian cancer. *Biochim Biophys Acta Rev Cancer*. 2019;1872(2):188307